An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

Bewley, Anthony; Barker, Erin T.; Baker, Hannah; Green, Will; Avey, Brooke; Pi-Blanque, Aina; Galván, Jordi; Trebbien, Paw; Præstegaard, Morten

doi:10.1080/09546634.2022.2116924

Cited by 7 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…In the absence of head-to-head RCTs, two MAIC analyses were recently undertaken to evaluate the efficacy of the Cal/BD cream versus the Cal/BD foam when used for the recommended treatment duration (8 weeks for cream and 4 weeks for foam) [ 46 , 47 ]. The analysis by Bewley and collaborators reported comparable effectiveness (i.e., no statistically significant difference) at the recommended treatment durations for cream and foam [ 46 ]. However, a MAIC analysis of five different trials by Papp et al consistently showed that Cal/BD foam treatment for 4 weeks induced a significantly higher PGA success than 8 weeks of the Cal/BD cream, with an even greater difference seen between the two formulations after 4 weeks of each treatment [ 47 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature

Fargnoli,

De Simone,

Gisondi

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Several comprehensive and updated guidelines are available on the management of psoriasis with systemic treatments. However, there is a lack of updates in recommendations and guidelines on topical treatments, particularly regarding the latest evidence and developments in treatment formulations. Consequently, a comprehensive literature review on this topic, considering the continuous evolution of knowledge and evaluation of the relevance of the available literature evidence, represents a current need to improve the topical management of psoriasis. This study critically appraises the available literature on all topical treatments of psoriasis from the past 20 years to address some relevant issues, such as the vehicle associated with the highest effectiveness, the best vehicle for improving patient adherence, and the best strategy in terms of efficacy and safety for long-term treatment. The greater effectiveness of the foam formulation was demonstrated for calcipotriene/betamethasone dipropionate (Cal/BD) administration compared with the gel and ointment. Without a direct comparison, matching-adjusted indirect comparison analyses support the superiority of the foam versus the cream overall. In addition, the reduced treatment period required by the Cal/BD foam (4 weeks) may favor this formulation over cream (8 weeks). The literature evidence, supported by a broad clinical experience, reported high rates of acceptability and adherence for the foam vehicle. A growing consensus is shared among dermatologists sustaining the proactive approach as the best option for the long-term topical treatment of psoriasis in adults. The Cal/BD foam is the only treatment for which the approved label allows biweekly maintenance use (proactive management), thus representing the first option for long-term topical treatment. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-023-01024-9.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature

Fargnoli,

De Simone,

Gisondi

et al. 2023

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

show abstract

“…These indirect comparisons were conducted without the exclusion of severe patients, nor adjustment on prognostic factors such as baseline severity or the other variables listed in Tables SI-SV, as that was not possible with the Bucher's adjusted indirect comparison method employed (7). Such an adjustment is feasible with the approach detailed here (10) and in a related MAIC of Cal/ BD cream vs foam that corroborates the similar impact on QoL of the 2 approved treatments (11). Moreover, Reich et al included MAICs of DLQI 0/1 response between on-and off-label Cal/BD cream and Cal/BD foam treatments to compare the same treatment durations; the results at 4 (off-label Cal/BD cream) and 8 (off-label Cal/ BD foam) weeks numerically favoured Cal/BD cream, but the differences were insignificant (7).…”

Section: Acta Dermato-venereologicamentioning

confidence: 97%

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis

Jalili,

Thoning,

Jablonski Bernasconi

et al. 2024

Acta Derm Venereol

View full text Add to dashboard Cite

show abstract

“…These two CAL/BDP foam trials were selected as they were the only ones sharing a common comparator with the CAL/BDP PAD-cream trials, the CAL/BDP gel. The presence of this common comparator allowed for an anchored matching-adjusted indirect comparison (MAIC) to be undertaken [ 24 ].…”

Section: Clinical Evidencementioning

confidence: 99%

“…Treatment satisfaction was measured with six equivalent questions from the PTCS of CAL/BDP PAD-cream trials and the Topical Product Usability Questionnaire (TPUQ) of the PSO-INSIGHTFUL study. The comparison of treatment satisfaction outcomes could only be made after one week of treatment because, in the PSO-INSIGHTFUL study, CAL/BDP foam and CAL/BDP gel were used only for one week, and this was the only study comparing the foam and gel formulations in these satisfaction and convenience variables [ 24 ].…”

Section: Clinical Evidencementioning

confidence: 99%

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Torres,

Galván,

Crutchley

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line choice in topical psoriasis treatment. A CAL/BDP cream based on polyaphron dispersion (PAD) Technology has emerged as a novel formulation for a more convenient topical treatment of psoriasis. This article aims to summarize the most relevant published evidence about CAL/BDP PAD-cream and its underlying PAD Technology. The PAD Technology enables CAL and BDP stability in an aqueous cream through a multimolecular shell structure, as well as it increases the penetration of both active ingredients into the epidermis and dermis. This technology also demonstrated to increase the cosmetic acceptability and to provide the desirable sensory properties for a topical psoriasis treatment. Two phase III clinical trials have been conducted so far with CAL/BDP PAD-cream. Findings from both trials revealed high efficacy with a fast onset of action, a favourable safety and tolerability profile and convenience for CAL/BDP PAD-cream compared to CAL/BDP gel. In the trial including patients with psoriasis affecting the scalp (MC2-01-C7), results support the use of CAL/BDP PAD-cream in scalp psoriasis. An anchored matching-adjusted indirect comparison (MAIC) was conducted to compare CAL/BDP PAD-cream and CAL/BDP foam, as both products had been previously compared to CAL/BDP gel. CAL/BDP PAD-cream and CAL/BDP foam showed equivalent efficacy and quality of life at their recommended treatment duration, whereas greater treatment satisfaction for CAL/BDP PAD-cream was found after one week of treatment. Overall, the high patient acceptability and treatment satisfaction observed with CAL/BDP PAD-cream in clinical trials may lead to improved adherence and hence higher efficacy in clinical practice.

show abstract

An anchored matching-adjusted indirect comparison of fixed-dose combination calcipotriol and betamethasone dipropionate (Cal/BDP) cream versus Cal/BDP foam for the treatment of psoriasis

Cited by 7 publications

References 24 publications

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature

Topical Treatment for the Management of Mild-to-Moderate Psoriasis: A Critical Appraisal of the Current Literature

Matching-adjusted Indirect Comparison of Dermatology Life Quality Index 0/1 Response in Trials of Calcipotriol Plus Betamethasone Dipropionate Foam and Cream Formulations in Patients with Psoriasis

Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review

Contact Info

Product

Resources

About